By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Hematologic Diseases and Conditions - Post-Thrombotic Syndrome. According to news reporting from Oslo, Norway, by NewsRx journalists, research stated, “Despite treatment of acute deep vein thrombosis (DVT) with low molecular weight heparin and warfarin, up to 50% of patients develop post-thrombotic syndrome (PTS). Our aims were to assess whether treatment of DVT with rivaroxaban would reduce the rate of subsequent PTS and improve health-related quality of life (HRQoL) as compared to conventional anticoagulation with low molecular weight heparin (LMWH)/warfarin.”
The news correspondents obtained a quote from the research from the University of Oslo, “Consecutive patients with an objectively confirmed DVT diagnosed between 2011 and 2014 and treated with either rivaroxaban or warfarin were included in this study 24 (+/- 6) months after DVT. PTS was assessed using the Patient Reported Villalta scale. HRQoL was assessed using the EQ-5D-3L and VEINES-QOL/Sym questionnaires. Total 309 patients were included, 161 (52%) treated with rivaroxaban and 148 (48%) with warfarin. Rivaroxaban-treated patients had a lower rate of PTS (45%: 95% confidence interval [CI] 37 to 52) compared to those treated with warfarin (59%: 95% CI 51 to 66, absolute risk difference 14%: 95% CI 3 to 25, odds ratio (OR) 0.6, P=. 01). The adjusted OR for development of PTS was 0.5 (95% CI: 0.3 to 0.8, P=. 01) in patients treated with rivaroxaban. HRQoL was significantly better in the rivaroxaban-treated patients. HRQoL measured by EQ-VAS (P=. 002) and VEINES-QOL/Sym (P=. 005/P=. 003) remained significantly better after adjustment. Patients treated with rivaroxaban had lower rate of PTS and better HRQoL after DVT compared to patients treated with warfarin.”
According to the news reporters, the research concluded: “However, these results should be interpreted with caution due to the limitation imposed by study design.”
For more information on this research see: Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thrombosis Research , 2018;163():6-11. Thrombosis Research can be contacted at: Pergamon-Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. (Elsevier - www.elsevier.com; Thrombosis Research - http://www.journals.elsevier.com/thrombosis-research/)
Our news journalists report that additional information may be obtained by contacting K.K. Utne, University of Oslo, Inst Clin Med, Oslo, Norway. Additional authors for this research include A. Dahm, H.S. Wik, L.P. Jelsness-Jorgensen, P.M. Sandset and W. Ghanima.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.thromres.2018.01.013. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
CITATION: (2018-04-27), New Post-Thrombotic Syndrome Study Findings Recently Were Reported by Researchers at University of Oslo (Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome), Health & Medicine Week, 1419, ISSN: 1532-4605, BUTTER® ID: 015562560
From the newsletter Health & Medicine Week.
https://www.newsrx.com/Butter/#!Search:a=15562560
This is a NewsRx® article created by NewsRx® and posted by NewsRx®. As proof that we are NewsRx® posting NewsRx® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.
We have been in business for more than 20 years and our full contact information is available on our main corporate website.
We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.
NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.